Navigation Links
Baron and Budd Supports the Newest Drug Being Tested for Mesothelioma Treatment
Date:8/5/2013

LOS ANGELES (PRWEB) August 05, 2013

Baron and Budd is proud to announce the Food and Drug Administration’s approval of a new drug to be used for the treatment of the rare cancer, mesothelioma, that occurs because of exposure to asbestos. This new drug is called VS-6036, or defactinib, and is a cancer-stem-cell inhibitor that is manufactured by Verastem Inc. (VSTM). (http://online.wsj.com/article/BT-CO-20130724-707069.html?mod=googlenews_wsj)

VS-6036 is being developed thanks to the Food and Drug Administration’s orphan drug designation that assists the development of drugs treating rare conditions affecting 200,000 patients or less within the U.S. With this designation, VS-6036 has been given assistance from the Food and Drug Administration in clinical trial development, pardon from the standard Food and Drug Administration user fees and a seven-year market exclusivity period after approval. (http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm)

Up to 400 patients are planned to enroll in clinical trial sites in 11 countries for the VS-6036 clinical study for patients suffering from pleural mesothelioma.

“We are encouraged by the work of the FDA and Verastem Inc. to better the lives of those suffering from mesothelioma," said Russell Budd of Baron and Budd. “While the FDA and Verastem Inc. prepare the VS-6036 clinical trial, we will continue to work to make sure that one day the need for mesothelioma treatment is irrelevant. We believe that a global ban on asbestos is imperative."

To find out more about asbestos exposure, mesothelioma and the road toward banning asbestos use within the United States, visit http://baronandbudd.com/areas-of-practice/mesothelioma-attorney/

Baron and Budd is an active participant in asbestos advocacy and mesothelioma education on a national scale. The law firm supports the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the countries’ top cancer treatment centers. With financial support from Baron and Budd, the NCCN has been able to produce and distribute a treatment resource detailing the Clinical Guidelines for Mesothelioma, titled the Patient Guidelines for Mesothelioma. Baron and Budd is also a repeat platinum sponsor of an international non-profit organization committed to banning asbestos and assisting patients suffering from mesothelioma, the Asbestos Disease Awareness Organization (ADAO). Baron and Budd was also an inaugural donor to the International Mesothelioma Program (IMP) at Brigham and Women’s Hospital in Boston.

Read the full story at http://www.prweb.com/releases/2013/8/prweb10993175.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
2. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
3. Study Supports Value of Sigmoidoscopy, an Alternative to Colonoscopy
4. Study supports urate protection against Parkinsons disease, hints at novel mechanism
5. Dietary fiber alters gut bacteria, supports gastrointestinal health
6. Narconon Louisiana Supports United Nations International Day Against Drug Abuse and Illicit Trafficking
7. NIDA supports development of combined anti-heroin and HIV vaccine
8. Little evidence supports autism treatment options in adolescents
9. $1.8 million grant supports investigation of psoriasis link to cardiovascular disease
10. John Templeton Foundation grant supports Princeton neuroscientists to study cognitive control
11. Human umbilical cord blood cell co-culture supports embryonic stem cell expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Emergency Physician and ... of the Outlier Leadership Series, Outliers in Writing, set to publish in summer 2017. ... Emergency Medicine at the University of Arizona College of Medicine. He also serves as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... ... Emmanuel College is introducing enhancements to its RN-to-BSN Degree ... fall of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a Bachelor ... as little as $14,528. These changes will enable nurses to complete their degree in ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier ... position. The former overall number one pick in the 2001 NFL Draft, to the ... the record for the most career rushing yards by a quarterback (6,109) and the ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... 2017  Astute Medical, Inc., developer of biomarkers for ... presented at the 2017 National Kidney Foundation (NKF) ... through April 22. Physicians will present data on two ... risk for acute kidney injury (AKI) during the management ... Elevated levels of TIMP-2 and IGFBP-7 have ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
(Date:4/18/2017)... Mass. , April 18, 2017  Spero Therapeutics, ... for the treatment of bacterial infections, will present preclinical ... the treatment of multidrug resistant (MDR) Gram-negative infections at ... Diseases (ECCMID) April 22-25, 2017 in Vienna, ... ...
Breaking Medicine Technology: